Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue
to be challenging at both the patient and programme level. The World Health Organization …

Treatment outcomes for multidrug-resistant (MDR) tuberculosis (TB) are poor with only
approximately 50% of patients attaining treatment success [1]. An important driver of …

Recently, the World Health Organization (WHO) released the updated guideline on the
treatment for multi-drug resistant tuberculosis (MDR-TB) treatment regimens based on new …

The importance of adequately managing multidrug-resistant (MDR) and extensively drug-
resistant (XDR) tuberculosis (TB) cases for TB control and elimination are underlined in the …

Background Evaluation of novel anti-tuberculosis (TB) drugs for the treatment of multidrug-
resistant (MDR)-TB continues to be of high interest on the TB research agenda. We …

The issuance of the WHO interim policy guidance for the use of bedaquiline represented a
major milestone in the treatment and care of multidrug-resistant tuberculosis (MDR-TB) 1 …

Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis
(MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients …

Abstract The World Health Organization (WHO) recommends countries introduce new anti-
TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to …

The World Health Organization (WHO) estimated that 490 000 cases of multidrug-resistant
(MDR) tuberculosis (TB)(defined as TB caused by Mycobacterium tuberculosis strains …

Background This retrospective cohort study assessed benefits and risks of bedaquiline
treatment in multidrug-resistant-tuberculosis (MDR-TB) combination therapy by evaluating …